Halobetasol Propionate Ointment Recalled for cGMP Deviations
Teligent Pharma is recalling all unexpired Halobetasol Propionate Ointment 0.05% due to current Good Manufacturing Practice (cGMP) deviations. The firm has discontinued its stability study program.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall for cGMP deviations related to a discontinued stability study program. The source does not report any illnesses, injuries, or adverse events—the hazard is manufacturing-practice noncompliance rather than a direct safety threat. This qualifies as a moderate, precautionary recall.
Plain-English summary
Teligent Pharma, Inc. is recalling Halobetasol Propionate Ointment 0.05% in two package sizes: 15 g tubes (NDC 52565-073-15) and 50 g tubes (NDC 52565-073-51). The recall affects 161,331 tubes distributed nationwide in the USA and Puerto Rico.
The recall is issued due to current Good Manufacturing Practice (cGMP) deviations. The firm has discontinued its stability study program, prompting the recall of all products within expiration dates across multiple batch numbers with expiration dates ranging from 2/28/2022 through 7/31/2023.
Consumers who have this product should stop using it and consult with their healthcare provider or pharmacist regarding their treatment options. Healthcare providers and patients with questions should contact Teligent Pharma or the FDA.
The recalled product
- Product
- Halobetasol Propionate Ointment, 0.05%, packaged as a) 15 g tubes, NDC 52565-073-15; b) 50 g tubes, NDC 52565-073-51, Rx Only, Manufactured by: Teligent Pharma, Inc., Buena, NJ 08310.
- Manufacturer
- Teligent Pharma, Inc.
- Hazard
- cgmp-deviation
- stability-study-discontinued
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Batch: a) 15280
- Exp. 2/28/2022
- 16539
- Exp. 3/31/2023
- 16907
- Exp. 5/31/2023
- b) 15381
- Exp. 3/31/2022
- 15382
- 15501
- 15523
- Exp. 4/30/2022
- 15812
- Exp. 7/31/2022
- 15972
- 16034
- 16037
- Exp. 9/30/2022
- 16105
- 16143
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- HighBeak & Skiff Alcohol Antiseptic Sanitizer recalled for acetaldehyde contamination
FDA (Drugs) · 2026-06-17
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27